Contact Us

HER2-Negative Breast Cancer Market Overview 2025: Size, Share & Growth Analysis

29 Apr, 2025

The HER2-Negative Breast Cancer Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.

What are the Historical Growth Trends in the HER2-Negative Breast Cancer Market?

The market size of HER2-negative breast cancer has experienced significant growth lately. The market value is projected to increase from $16.29 billion in 2024 to $17.62 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.1%.

What are the 2025 Market Projections: Forecasted Size & Growth Rate for the HER2-Negative Breast Cancer Industry?

The HER2-negative breast cancer market is predicted to expand to $23.86 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%.

Download Your Free Sample of the 2025 HER2-Negative Breast Cancer Market Report and Uncover Key Trends Now!

What are the Key Growth Drivers Fueling the HER2-Negative Breast Cancer Market?

The key drivers in the her2-negative breast cancer market are:

• Rising alcohol consumption
• Escalating adoption of unhealthy lifestyles
• Growing prevalence of obesity
• Increasing tobacco usage

Global Market Segmentation: Identifying Major HER2-Negative Breast Cancer Industry Segments

The HER2-negative breast cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy
2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments:
1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

Pre-order the 2025 HER2-Negative Breast Cancer Global Market Report for Fast Delivery & Comprehensive Insights!

What are the emerging Trends Shaping the Future of the HER2-Negative Breast Cancer Market?

The key trends in the her2-negative breast cancer market are:

• One emerging trend is the innovation in diagnostic technologies.
• Targeted therapies are becoming increasingly integrated, indicating a new trend.
• The integration of immunotherapies is also seen as a significant emerging trend.
• FDA approvals and technological advancements are shaping the future of the market too.

Who Are the Top Competitors & Leading Players in the HER2-Negative Breast Cancer Market?

Major players in the her2-negative breast cancer market are:

• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Sanofi S.A.
• AstraZeneca PLC
• Novartis International AG
• Eli Lilly and Company
• Amgen Inc.
• Daiichi Sankyo Company Limited
• Jiangsu Hansoh Pharmaceutical Co. Ltd.
• BeiGene Ltd.
• Chipscreen Biosciences Ltd.
• F. Hoffmann-La Roche Ltd
• PharmAbcine Inc.
• Adagene Inc.
• H3 Biomedicine Inc.
• Radius Health Inc.
• Zenith Epigenetics Ltd.

Regional Dominance: Which Area Leads the Global Template Market?

North America was the largest region in the HER2-negative breast cancer market in 2024